Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination
Marwa AlMadhi, Abdulla AlAwadhi, Nigel Stevenson, Khalid Greish, Jaleela Jawad, Adel Alsayyad, Afaf Mirza, Basma Alsaffar, Ejlal AlAlawi, Khulood Fakhroo, Batool Alalawi, Lana Alabbasi, Noora Aljalahma, Manaf AlQahtani
doi: https://doi.org/10.1101/2022.08.24.22279160
Marwa AlMadhi
1National Taskforce for Combating the Coronavirus (COVID-19), Bahrain
2University of Manchester, United Kingdom
Abdulla AlAwadhi
1National Taskforce for Combating the Coronavirus (COVID-19), Bahrain
3Bahrain Defence Force Hospital, Bahrain
Nigel Stevenson
4Royal College of Surgeons in Ireland, Dublin, Ireland
Khalid Greish
5Arabian Gulf University, Manama, Bahrain
Jaleela Jawad
6Ministry of Health, Bahrain
Adel Alsayyad
6Ministry of Health, Bahrain
7Public Health Directorate, Bahrain
Afaf Mirza
6Ministry of Health, Bahrain
7Public Health Directorate, Bahrain
Basma Alsaffar
6Ministry of Health, Bahrain
Ejlal AlAlawi
6Ministry of Health, Bahrain
Khulood Fakhroo
6Ministry of Health, Bahrain
Batool Alalawi
8Public Health Directorate Laboratory, Bahrain
Lana Alabbasi
9Royal College of Surgeons in Ireland, Bahrain
Noora Aljalahma
9Royal College of Surgeons in Ireland, Bahrain
Manaf AlQahtani
1National Taskforce for Combating the Coronavirus (COVID-19), Bahrain
3Bahrain Defence Force Hospital, Bahrain
9Royal College of Surgeons in Ireland, Bahrain
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author
Posted August 24, 2022.
Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination
Marwa AlMadhi, Abdulla AlAwadhi, Nigel Stevenson, Khalid Greish, Jaleela Jawad, Adel Alsayyad, Afaf Mirza, Basma Alsaffar, Ejlal AlAlawi, Khulood Fakhroo, Batool Alalawi, Lana Alabbasi, Noora Aljalahma, Manaf AlQahtani
medRxiv 2022.08.24.22279160; doi: https://doi.org/10.1101/2022.08.24.22279160
Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination
Marwa AlMadhi, Abdulla AlAwadhi, Nigel Stevenson, Khalid Greish, Jaleela Jawad, Adel Alsayyad, Afaf Mirza, Basma Alsaffar, Ejlal AlAlawi, Khulood Fakhroo, Batool Alalawi, Lana Alabbasi, Noora Aljalahma, Manaf AlQahtani
medRxiv 2022.08.24.22279160; doi: https://doi.org/10.1101/2022.08.24.22279160
Subject Area
Subject Areas
- Addiction Medicine (358)
- Allergy and Immunology (681)
- Anesthesia (182)
- Cardiovascular Medicine (2701)
- Dermatology (231)
- Emergency Medicine (407)
- Epidemiology (12342)
- Forensic Medicine (10)
- Gastroenterology (774)
- Genetic and Genomic Medicine (4186)
- Geriatric Medicine (393)
- Health Economics (690)
- Health Informatics (2707)
- Health Policy (1012)
- Hematology (366)
- HIV/AIDS (869)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (447)
- Neurology (3974)
- Nursing (216)
- Nutrition (587)
- Oncology (2093)
- Ophthalmology (597)
- Orthopedics (245)
- Otolaryngology (309)
- Pain Medicine (254)
- Palliative Medicine (76)
- Pathology (474)
- Pediatrics (1137)
- Primary Care Research (464)
- Public and Global Health (6602)
- Radiology and Imaging (1432)
- Respiratory Medicine (879)
- Rheumatology (416)
- Sports Medicine (347)
- Surgery (458)
- Toxicology (56)
- Transplantation (192)
- Urology (170)